The influence of compression on the phase behavior of amorphous solid dispersions. K.U.Leuven Abstract: The objective of the current project is to understand the physics of compression induced phase separation and to find a solution for the compression related stability problem i) by elucidating the importance of compression forces on the phase stability of amorphous solid dispersions made up of model drugs with various physical-chemical profile and pharmaceutically relevant polymers; ii) by unraveling the influence of tablet additives (energy dissipation possibility) on the phase stability; and iii)by clarifying the influence of drug-polymer interactions on compressioninduced phase separation. Moreover, the outcome of this research project will lead to the development of a new test to evaluate the stability of amorphous solid dispersions during the developmental phase: next to studying the influence of heat and humidity, compression can be applied for stability testing. Organisations:
• Guy Van den Mooter• Jan Van Humbeeck
Venomics and transcriptomics of Conus spp.: an untapped treasure for drug discovery. K.U.Leuven Abstract: Ongeveer 500 verschillende zeeslak species (cone snails) zijn bekend, die elk een ongelooflijke repertorium van farmacologisch actieve stoffen produceren met een unieke selectiviteit en potentie. Vandaag de dag bestaan er conopeptide-gebaseerde behandelingen, vnl. gefocusseerd op bepaalde vormen van pijn en epilepsie. Daarentegen zijn toepassing zoals neuroprotectie in getraumatisieerde hersenen, aandoeningen van het ruggemerg en beroerte nog niet aangetoond of bekend. In dit licht is daarom de belangrijkse mijlpaal voor onze postdoc 'venomics': d.w.z. de ontdekking en karakterisernig van zeer specifieke en potente conopeptiden (toxines) die ionen kanaal (of receptoren) activiteit kunnen modeleren. Deze ionen kanalen (of receptoren) speel een rol in pijn, epilepsie, ataxia en convulsies. Verder zal de postdoc onderzoek doen naar de ontdekking van conopeptiden (toxines) die als therapeutische moleculen kunnen ingezetworden bij ionen kanalen (of receptoren) geassocieerd met erfelijke aan Organisations:
Investigating the relation of regional myocardial function and metabolism to id entify non-invasive parameters for the prediction of disease progressionerapy success in patients with dilated cardiomyopathy. K.U.Leuven Abstract: No English Abstract Organisations:
• Filip Rega• Olivier Gheysens• Kathleen Vunckx• Jens-Uwe Voigt
The role of the Fragile X Mental Retardation Protein as a possible prognostic marker to gauge Cancer Metastasis. K.U.Leuven Abstract: not applicable Organisations:
Transient Receptor Potential cation channels as endotoxin sensors in Drosophila. K.U.Leuven Abstract: No English Abstract Organisations:
• Karel Talavera Pérez• Bassem Hassan
Clinical impact of protein aggregation in cancer. K.U.Leuven Abstract: No English Abstract Organisations:
Functional segregation and integration in the cortical circuits for language and selective attention and the effects of focal lesions and cortical neurodegenerative disease. K.U.Leuven
Abstract: No English AbstractOrganisations:
• Research Group Experimental Neurology
Listening with age: disentangling peripheral and cortical processing inthe aging auditory system. K.U.Leuven Abstract: In daily life most speech communication information has to be captured in non-optimal acoustical environments and in the presence of interfering sound sources. In the auditory system, the complex speech signal needsto be analyzed acoustically and neurally, separated from the noise, andmapped to phonemes and words. This processing is found to be significantly affected by age. The elderly have more difficulties to follow the rapid temporal patterns of speech, to understand speech in the presence ofa competing talker or noise, and to use the inter-aural cues of signalsfor understanding speech in spatially separated noise. Many of these observations are related to changes with age in the status of the peripheral auditory sensory system (the inner ear) and/or in the abilities of more central neural processes. Several of these issues have been studied before using behavioral measures (audiogram, speech understanding tests).However, while these functional measures yield importanbsp;nt informa Organisations:
• Research Group Experimental Oto-rhino-la
Pattern recognition for gait analysis: Integration of clinical expert knowledge and machine learning techniques. K.U.Leuven Abstract: No English Abstract Organisations:
• Research Group for Neuromotor Rehabilita
• Katleen Desloovere• Guy Molenaers• Tinne De Laet
Nutrient mediated modulation of the oral microbiota. K.U.Leuven Abstract: No English Abstract Organisations:
• Marc Quirynen• Kristel Bernaerts• Wim Teughels
The role of unstable tandem repeats in human evolution and disease. K.U.Leuven Abstract: No English Abstract Organisations:
• Guido Froyen• Kevin Verstrepen• Alena Zablotskaya
Evaluation of galectin-1 targeting drugs in combination with chemo-immunotherapy in the treatment of high-grade glioma. K.U.Leuven Abstract: No English Abstract Organisations:
• Research Group Experimental Neurosurgery
• Stefaan Van Gool• Steven De Vleeschouwer• Matthias Van Woensel
Gut-Brain Interactions in Visceral Pain and the Regulation of Food Intake. K.U.Leuven Abstract: Neurohumoral gut-brain signals are part of an integrated interoceptive system which is continuously signaling homeostatic information to the brain; normally this remains largely unperceived. Dysfunctional gut-brain signaling has been implicated in both functional (i.e. unexplained) gastrointestinal (GI) disorders, characterized by visceral pain, and food intake disorders, such as obesity. Both groups of conditions are highly prevalent and associated with low quality of life and high healthcare costs. The aim of this research project is to further elucidate the brain mechanisms underlying processing and modulation of gut-brain signals in health and functional GI food intake disorders. Based on our previous research, we will address three hypotheses:1. Affective processes influence visceral sensitivity through the descending modulatory system.2. Nutrient-induced gastric distension deactivates pain-processing brain regions through interacting bottom-up and top-down mechanisms. 3. Inte Organisations:
• Translational Research in GastroIntestin
Identification and development of new classes of immunosuppressive compounds and discovery of new key proteins involved in the T and B-cell activation. K.U.LeuvenAbstract: No English AbstractOrganisations:
• Piet Herdewyn• Jean Herman• Yves Moreau• Lieven Thorrez• Thierry Louat
The pathophysiology of esophageal mobility disorders revisited using automated impedance manometry measurements K.U.Leuven Abstract: No English Abstract Organisations:
• Research Group Experimental Oto-rhino-la
• Jan Tack• Nathalie Rommel• Charlotte Scheerens
Partial Volume Correction of Cardiac PET using Anatomy Information fromCT and MRI K.U.Leuven Abstract: No English Abstract Organisations:
• Piet Claus• Jens-Uwe Voigt• Anna Turco
Ribosome Mutations in Leukemia Development K.U.Leuven Abstract: No English Abstract Organisations:
• Kim De Keersmaecker• Tiziana Girardi
The effect of compression forces on the phase behavior of amorphous solid dispersions K.U.Leuven Abstract: No English Abstract Organisations:
• Guy Van den Mooter• Jan Van Humbeeck• Abhishek Singh
Dissecting the immunological and molecular mechanisms of gain-of-function NOD2 mutations in Blau Syndrome and Early Onset Sarcoidosis. K.U.Leuven Abstract: Blau Syndrome (BS) and Early Onset Sarcoidosis (EOS) are rare monogenicautoinflammatory diseases characterized by a clinical triad of granulomatous arthritis, uveitis and rash. Extended manifestations with potentially high morbidity have been reported recently. The pathologic hallmark of BS/EOS is the presence of multinucleated giant cell and epithelioid cell granulomas in affected tissues. Both diseases are associated with gain-of-function mutations in the NOD2 gene. NOD2 is a specialised intracellular protein that plays a critical role in the regulation of the host innate immune response through recognising conserved microbial molecularsignatures, thus leading to the induction of pro-inflammatory and anti- microbial responses as well as apoptosis. While the genetic basis of BS/EOS has been characterized, the molecular mechanisms by which NOD2 mutations drive granuloma formation and the development of sarcoidosis remainunclear. A better understanding of thesemechanisms is of direct rel Organisations:
• Laboratory of Genetics of Autoimmunity
• Carine Wouters• Adrian Liston• Lien Van Eyck
The molecular pathogenesis of Fuchs' endothelial corneal dystrophy. K.U.Leuven Abstract: Fuchs endothelial corneal dystrophy is a disorder in which the outerlayer of the eye (the cornea) becomes blurred and consequently vision becomes impaired. It was first described one century ago by Fuchs. Subsequent investigations revealed that the cause of this disorder resides in the inner layer of the cornea: the corneal endothelium. In normal conditions these endothelial cells keep the cornea lucid by pumping away excess tear fluid. A dysfunction or dystrophy of these cells results in corneal clouding and impaired vision. The current treatment consists in replacing the affected endothelium by healthy donor endothelium. This therapy works well. However no one exactly knows the underlying molecular mechanisms behind the dysfunction of these cells and why the cornea becomes blurred. By understanding the underlying mechanisms, one could try and develop less invasive, non-surgical (drug)therapies that would intervene at the molecular level of the disease, thereby preventing the d Organisations:
• Translational Cell & Tissue Research
§ 90-92. Schedule IV controlled substances. This schedule includes the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated. In determining that a substance comes within this schedule, the Commission shall find: a low potential for abuse relative to the substances listed in Schedule III of this Article; currentl
CLIENT HEALTH INFORMATION SHEET PERSONAL DATA: Name: ________________________________ Date: ______________________________ Birthday: ______________________________ Phone (home):_______________________ Address: _______________________________ Phone (cell): ________________________ City/State/Zip: ________________________________________________________________ Primary Health Care Provider: